Investment fund Villere St Denis J & Co LLC completely exited its position in Euronet Worldwide, selling 244,878 shares worth approximately $17.53 million in Q1 2026. The liquidation represents a full exit from a position that previously comprised 1.9% of the fund's assets under management. Euronet shares have declined 25.4% over the past year, underperforming the S&P 500 significantly.

The Schall Law Firm is investigating potential breaches of fiduciary duty by XOMA Royalty Corporation's board and management regarding the company's $739 million acquisition by Ligand Pharmaceuticals. Shareholders are invited to participate in the investigation.

Ligand Pharmaceuticals announced the acquisition of XOMA Royalty Corporation for $739 million ($39.00 per share in cash). The deal is expected to be immediately accretive to adjusted EPS and increases Ligand's 2026 guidance to $8.50-$9.50 per share, with an additional $1.50 per share contribution expected in 2027. The acquisition expands Ligand's royalty portfolio and strengthens its position as a leading biopharma royalty aggregator.

Monteverde & Associates PC announced investigations into multiple companies involved in M&A transactions, including XOMA Royalty Corporation's proposed sale to Ligand Pharmaceuticals at $39.00 per share in cash. The firm is examining whether the deal terms are fair to shareholders.

Ligand Pharmaceuticals announced it will acquire XOMA Royalty Corporation for $39.00 per share in cash, totaling approximately $739 million. The acquisition expands Ligand's royalty portfolio to over 200 assets and adds seven commercial products. Ligand raised its 2026 adjusted EPS guidance to $8.50-$9.50 and expects the transaction to be accretive by $1.50 per share in 2027. The deal is expected to close in Q3 2026.

Ligand Pharmaceuticals CFO Octavio Espinoza sold 3,057 shares worth $688,000 on March 11, 2026, representing 12.70% of his direct holdings. The sale was executed under a prearranged 10b5-1 plan and appears to be a structured liquidity event rather than a red flag. Despite the insider sale, Ligand's fundamentals remain strong with 2025 revenue reaching $268.1 million (60% increase) and net income of $124.5 million, with management forecasting up to $285 million in revenue for 2026.

Bank of America Securities initiated coverage of Ligand Pharmaceuticals with a Buy rating and $244 price target, highlighting the biopharmaceutical royalty aggregator's differentiated business model, strong management, and attractive growth prospects. The company beat Q4 earnings expectations with $2.02 EPS versus $1.56 consensus and $59.7M in sales versus $55.6M estimate, while maintaining fiscal 2026 guidance of $8.00-$9.00 EPS and $245-$285M in sales.

Ashford Capital Management increased its stake in Vicor by 128,664 shares worth $10.94 million in Q4 2025, bringing its total position to $38.78 million (4.32% of assets). The investment comes as Vicor stock has surged 213% over the past year, driven by strong Q3 results showing 18.5% revenue growth and 57.5% gross margins. The fund's confidence suggests belief in structural demand for Vicor's high-performance power conversion technology in AI and data center infrastructure.

Ashford Capital Management sold 19,607 shares of Cavco Industries (CVCO) worth approximately $11.11 million in Q4 2025, reducing its position from 3.1% to 1.87% of fund assets. The sale appears to be a capital reallocation rather than a loss of conviction, as Cavco's fundamentals remain solid with Q3 revenue up 11.3% year-over-year, though the stock has underperformed the S&P 500 by 1.5 percentage points over the past year.

Ligand Pharmaceuticals announced 2026 full year revenue guidance of $245-$285 million, representing a 15% core revenue growth, with strong expectations for royalty revenue from key pharmaceutical products.

Pelthos Therapeutics signed an agreement with a major Pharmacy Benefit Manager to expand patient access to ZELSUVMI, its FDA-approved topical gel for treating molluscum contagiosum, which affects an estimated 16.7 million people annually.

SQ Innovation received FDA approval for Lasix® ONYU, an at-home subcutaneous treatment for edema in heart failure patients, utilizing Ligand's Captisol technology to create a novel high-concentration furosemide formulation.